Why Hydroxychloroquine 200mg is Not Effective in Adults Hospitalized with The Covid

Why Hydroxychloroquine 200mg is Not Effective in Adults Hospitalized with The Covid

Malaria and autoimmune disorders like Lupus and Rheumatoid Arthritis can be treated with Hydroxychloroquine, a prescription medicine. Early findings showed that the medicine may help the virus patients, therefore it quickly garnered a lot of interest. Preliminary investigations in cells and short studies of the virus patients with no control groups were used to draw conclusions in these papers.

The FDA granted emergency use permission to doctors in March 2020, enabling them to provide hydroxychloroquine or the similar medicine chloroquine to hospitalized virus patients. Many institutions now routinely use the medications to treat the covid virus patients. You can buy Hydroxychloroquine 200mg tablets at Ourmedicnes.com.

What is Hydroxychloroquine 200mg Used for and How does It Work?

A medicine known as hydroxychloroquine is used to treat rheumatoid arthritis, which is a kind of autoimmune disease (DMARD). Immune system activity, which might be excessive in some situations, is under control by this hormone. Rather than just treating the symptoms of an illness, hydroxychloroquine has the potential to affect the disease process itself.

Research on Hydroccychloroquine 

More comprehensive research was required to assess the safety and efficacy of hydroxychloroquine 200mg in the treatment of SARS-CoV-2 infection. The National Institutes of Health (NIH) began a clinical study of the medicine in April at 34 hospitals around the country. There is a National Heart, Lung, and Blood Institute (NIH) grant that supported this research (NHLBI).

The trial was halted in June due to preliminary data showing that the medicine did not cause any damage or enhance patient outcomes at that time. Of the anticipated 510 participants, the experiment has already enrolled 479. The FDA had previously removed hydroxychloroquine and chloroquine’s emergency use permission earlier this month. Risks, including significant cardiac rhythm abnormalities, were also noted.

The final examination of the data has been completed by researchers at Vanderbilt University led by Dr. Wesley Self. On November 9, 2020, their findings were published in the journal JAMA.

Test Results of Hydroxychloroquine

Hydroxychloroquine 200mg or a placebo was given to each of the 479 patients who signed up for the study. 290 Latino and Black volunteers were involved in the trial. The average age of the patients was 57. Over the course of five days, they were given 10 doses of either hydroxychloroquine or a placebo (400 mg twice daily on the first day, then 200 mg twice daily for the following four days).

Each patient’s condition was evaluated 14 days after they were allocated to a therapy group by researchers. Scales ranging from one (death) to seven were employed by the researchers, with one being the lowest and seven the highest (discharged from the hospital and able to perform normal activities). Hypochloroquine and placebo groups did not differ significantly in their outcomes.


The researchers also observed no differences in death 28 days after treatment assignment or time to recovery in any of the other 12 outcomes. They found that hydroxychloroquine 200mg was not an effective medication based on the evidence they collected.

In light of these findings, we expect that clinicians and researchers will be able to make better treatment options for individuals with this condition,” says Dr. James P. Kiley of the NHLBI.

Similar findings were seen in the UK and Brazil. More than 250,000 people have died in the United States as a result of the virus, which is still under investigation by researchers. Find more about Hydroxychloroquine 200mg Tablets.

Leave a Reply

Your email address will not be published. Required fields are marked *